Imdusiran

DRUG2 trials

Sponsors

Arbutus Biopharma Inc., Arbutus Biopharma Corporation

Conditions

Chronic HBV InfectionHepatitis B, Chronic

Phase 2

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

WithdrawnNCT06245291

Arbutus Biopharma CorporationHepatitis B, Chronic

Start: 2024-05-01End: 2024-08-01Updated: 2024-08-12

A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection

CompletedCTIS2023-509573-23-00

Arbutus Biopharma Inc.Chronic HBV Infection

Start: 2024-07-16End: 2024-08-01Target: 13Updated: 2024-06-28